These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
183 related articles for article (PubMed ID: 27286661)
1. Proteasome inhibitor associated thrombotic microangiopathy. Yui JC; Van Keer J; Weiss BM; Waxman AJ; Palmer MB; D'Agati VD; Kastritis E; Dimopoulos MA; Vij R; Bansal D; Dingli D; Nasr SH; Leung N Am J Hematol; 2016 Sep; 91(9):E348-52. PubMed ID: 27286661 [TBL] [Abstract][Full Text] [Related]
2. Drug-induced Thrombotic Microangiopathy with Concurrent Proteasome Inhibitor Use in the Treatment of Multiple Myeloma: A Case Series and Review of the Literature. Monteith BE; Venner CP; Reece DE; Kew AK; Lalancette M; Garland JS; Shepherd LE; Pater JL; Hay AE Clin Lymphoma Myeloma Leuk; 2020 Nov; 20(11):e791-e800. PubMed ID: 32807717 [TBL] [Abstract][Full Text] [Related]
3. Carfilzomib-induced hemolysis is noticeably common but rarely shows features of thrombotic microangiopathy: A retrospective study. Kozlowski P; Kameran Behnam K; Uggla B; Åström M Eur J Haematol; 2020 Jun; 104(6):588-593. PubMed ID: 32115785 [TBL] [Abstract][Full Text] [Related]
6. Microangiopathy in multiple myeloma: a case of carfilzomib-induced secondary thrombotic microangiopathy successfully treated with plasma exchange and complement inhibition. Catanese L; Link K; Rupprecht H BMC Nephrol; 2023 Jun; 24(1):179. PubMed ID: 37337151 [TBL] [Abstract][Full Text] [Related]
8. Two cases of carfilzomib-induced thrombotic microangiopathy successfully treated with Eculizumab in multiple myeloma. Rassner M; Baur R; Wäsch R; Schiffer M; Schneider J; Mackensen A; Engelhardt M BMC Nephrol; 2021 Jan; 22(1):32. PubMed ID: 33461512 [TBL] [Abstract][Full Text] [Related]
9. Renal and pulmonary thrombotic microangiopathy triggered by proteasome-inhibitor therapy in patient with smoldering myeloma: A renal biopsy and autopsy case report. Cassol CA; Williams MPA; Caza TN; Rodriguez S Medicine (Baltimore); 2019 Sep; 98(39):e17148. PubMed ID: 31574818 [TBL] [Abstract][Full Text] [Related]
10. Carfilzomib: A cause of drug associated thrombotic microangiopathy. Qaqish I; Schlam IM; Chakkera HA; Fonseca R; Adamski J Transfus Apher Sci; 2016 Jun; 54(3):401-4. PubMed ID: 27017313 [TBL] [Abstract][Full Text] [Related]
11. Clinical features, treatment, and outcomes of patients with carfilzomib induced thrombotic microangiopathy. Fang W; Sun W; Fang W; Zhao S; Wang C Int Immunopharmacol; 2024 Jun; 134():112178. PubMed ID: 38728883 [TBL] [Abstract][Full Text] [Related]
12. Influenza-induced thrombotic microangiopathy in a patient with cancer on proteasome inhibitor: a diagnostic dilemma. Hamad CD; Hoelscher ZC; Tchakarov A; Kala J CEN Case Rep; 2022 Aug; 11(3):321-327. PubMed ID: 34997535 [TBL] [Abstract][Full Text] [Related]
13. Carfilzomib-induced thrombotic microangiopathy. A case report. Scheggi V; Merilli I; Cesaroni E; Alterini B J Oncol Pharm Pract; 2022 Apr; 28(3):754-758. PubMed ID: 34904466 [TBL] [Abstract][Full Text] [Related]
14. Carfilzomib-induced thrombotic microangiopathy (TMA): an under-recognised spectrum of disease from microangiopathic haemolysis to subclinical TMA. Ponraj R; Bryant A; Dunlop L; Range H; Cobrador C; Ling S; Hsu D Blood Cancer J; 2023 Jul; 13(1):113. PubMed ID: 37495597 [No Abstract] [Full Text] [Related]
16. Complement as the enabler of carfilzomib-induced thrombotic microangiopathy. Blasco M; Martínez-Roca A; Rodríguez-Lobato LG; Garcia-Herrera A; Rosiñol L; Castro P; Fernández S; Quintana LF; Cibeira MT; Bladé J; Fernández de Larrea C; Tovar N; Jimenez R; Poch E; Guillen E; Campistol JM; Carreras E; Diaz-Ricart M; Palomo M Br J Haematol; 2021 Apr; 193(1):181-187. PubMed ID: 32469083 [TBL] [Abstract][Full Text] [Related]
17. Hemolysis and schistocytosis in the emergency department: consider pseudothrombotic microangiopathy related to vitamin B12 deficiency. Noël N; Maigné G; Tertian G; Anguel N; Monnet X; Michot JM; Goujard C; Lambotte O QJM; 2013 Nov; 106(11):1017-22. PubMed ID: 23842487 [TBL] [Abstract][Full Text] [Related]
18. Carfilzomib-induced thrombotic microangiopathy is underestimated in clinical practice: A report of five patients and literature review. Terao T; Tsushima T; Miura D; Ikeda D; Fukumoto A; Kuzume A; Tabata R; Narita K; Takeuchi M; Matsue K Leuk Lymphoma; 2022 May; 63(5):1102-1110. PubMed ID: 35373680 [TBL] [Abstract][Full Text] [Related]
19. A non-invasive laboratory panel as a diagnostic and prognostic biomarker for thrombotic microangiopathy: development and application in a Chinese cohort study. Zhang T; Chen H; Liang S; Chen D; Zheng C; Zeng C; Zhang H; Liu Z PLoS One; 2014; 9(11):e111992. PubMed ID: 25372665 [TBL] [Abstract][Full Text] [Related]
20. Mutations in the alternative complement pathway in multiple myeloma patients with carfilzomib-induced thrombotic microangiopathy. Moscvin M; Liacos CI; Chen T; Theodorakakou F; Fotiou D; Hossain S; Rowell S; Leblebjian H; Regan E; Czarnecki P; Bagnoli F; Bolli N; Richardson P; Rennke HG; Dimopoulos MA; Kastritis E; Bianchi G Blood Cancer J; 2023 Feb; 13(1):31. PubMed ID: 36849497 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]